

Ref No.: ZLL/CS/BSE/NSE

Date: 16.10.2026

BSE Limited, Corporate Relationship Department P. J. Towers, Dalal Street, Mumbai- 400 001 Company Code- 541400	National Stock Exchange of India Limited Listing Compliance Department Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)
---	---

Dear Sir/Madam,

Sub: Press Release for grant of TGA GMP Certification for the Manufacturing Facility of the Company

Please find enclosed herewith the Press Release relating to grant of Good Manufacturing Practice (GMP) Certification of Compliance by Australia's Therapeutic Goods Administration (TGA) to ZIM Laboratories Limited ("the Company") for the manufacturing facility of the Company at B-21/22, MIDC Area, Kalmeshwar, Nagpur, Maharashtra.

Request you to kindly take the same on your record.

Thanking you,

Yours faithfully,

For ZIM LABORATORIES LIMITED

Piyush
Siddheshwar
Nikhade

Digitally signed by Piyush Siddheshwar Nikhade
DN: cn=Piyush Siddheshwar Nikhade, o=ZIM Laboratories Limited, ou=ZIM Laboratories Limited, email=Piyush.Nikhade@zimlab.in, c=India
c=India, o=ZIM Laboratories Limited, ou=ZIM Laboratories Limited, email=Piyush.Nikhade@zimlab.in, c=India
3746951cd5119ca04, email=Piyush.Nikhade@zimlab.in, c=India
Date: 2026.10.16 12:46:41 +05'30'

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972

Encl.: As above

ZIM LABORATORIES LIMITED

PRESS RELEASE

ZIM Laboratories Limited Receives TGA GMP Certification for its Manufacturing Facility

Certification covers multiple dosage forms, including soluble films, wafers, tablets, capsules and granules

Nagpur, India | 16 October 2026: ZIM Laboratories Limited (“ZIM” or “the Company”) announces that it has received a Certificate of Good Manufacturing Practice (GMP) Compliance from Australia’s Therapeutic Goods Administration (TGA) for its manufacturing facility at B-21/22, MIDC Area, Kalmeshwar, Nagpur, Maharashtra.

Issued on 15 October 2026, the certification follows an on-site inspection conducted on 18 April and 20–21 April 2026. It confirms that the facility complies with the requirements of the PIC/S Guide to Good Manufacturing Practice for Medicinal Products dated 25 August 2023.

The certification covers the manufacture of non-sterile finished products across both registered and listed therapeutic goods categories. Its scope includes hard capsules, solid unit dosage forms, tablets, granules, powders for suspension, wafers and soluble films.

The certification supports the Company’s efforts to develop manufacturing partnerships and pursue opportunities in the Australian market, subject to applicable product-specific regulatory approvals.

Alongside supporting ZIM’s pursuit of opportunities in Australia, the certification is expected to strengthen the Company’s credentials in Rest of World (RoW) markets. It can provide supporting GMP evidence for regulatory submissions in countries that accept or rely on TGA inspection outcomes, subject to each jurisdiction’s requirements.

This milestone reinforces ZIM’s commitment to manufacturing quality, regulatory compliance and reliable supply. The breadth of the certified dosage forms provides a foundation for engaging with partners across a range of pharmaceutical product requirements.

The Certificate is valid until **21 June 2028**, subject to re-inspections being conducted as scheduled by the TGA. The certificate specifies that no further conditions apply to the manufacturing operations covered.

About ZIM Laboratories Limited

ZIM Laboratories Limited (the Company) is a research-driven pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments. The Company has state-of-the-art in-house R&D capabilities to offer innovative drug delivery solutions using proprietary technology platforms, aiming to enhance patent convenience and treatment adherence. ZIM Laboratories Limited is listed on the National Stock Exchange of India Limited (NSE) and BSE Limited.